Taltz (Ixekizumab), IL-17A Antagonist, Receives FDA Approval for Patients with Plaque PsoriasisLoretta Fala
Ixekizumabis highly effective inclinical trials, with higher response and clearance rates than other FDA-approvedpsoriasistreatment agents.12,16 Phase 2 Trial and Open-Label Extension Study A phase 2 double-blinded, multicenter, randomized, dose-ranging study was performed in 142 adults (18 years or...
Ixekizumab is approved for the treatment of r-axSpA, nr-axSpA, psoriasis and PsA by FDA [54], while EMA approval extends to nail psoriasis as well [55]. Ixekizumab has additionally demonstrated a treatment benefit in specific psoriasis locations including scalp, palmoplantar and genital psoriasis ...